Opko Health, Inc. (OPK)

$1.23

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Opko Health, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 178.6M → 181.9M (in $), with an average increase of 1.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -84.5M → -66.50M (in $), with an average increase of 27.1% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 14.9% return, outperforming this stock by 26.4%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 5.1% return, outperforming this stock by 75.3%

Performance

  • $1.22
    $1.24
    $1.23
    downward going graph

    0.81%

    Downside

    Day's Volatility :1.61%

    Upside

    0.81%

    downward going graph
  • $0.85
    $2.24
    $1.23
    downward going graph

    30.76%

    Downside

    52 Weeks Volatility :61.98%

    Upside

    45.09%

    downward going graph

Returns

PeriodOpko Health, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
21.78%
-0.4%
0.0%
6 Months
-4.65%
8.5%
0.0%
1 Year
-11.51%
4.2%
-1.2%
3 Years
-70.22%
13.9%
-19.2%

Highlights

Market Capitalization
857.3M
Book Value
$1.8
Earnings Per Share (EPS)
-0.25
PEG Ratio
-2.87
Wall Street Target Price
4.25
Profit Margin
-21.87%
Operating Margin TTM
-37.97%
Return On Assets TTM
-4.73%
Return On Equity TTM
-12.8%
Revenue TTM
863.5M
Revenue Per Share TTM
1.15
Quarterly Revenue Growth YOY
-1.9%
Gross Profit TTM
214.3M
EBITDA
-52.8M
Diluted Eps TTM
-0.25
Quarterly Earnings Growth YOY
0.19
EPS Estimate Current Year
-0.37
EPS Estimate Next Year
-0.26
EPS Estimate Current Quarter
-0.09
EPS Estimate Next Quarter
-0.06

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Opko Health, Inc.(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 245.53%

Current $1.23
Target $4.25

Company Financials

FY18Y/Y Change
Revenue
990.3M
↑ 2.51%
Net Income
-153.0M
↓ 49.88%
Net Profit Margin
-15.45%
↑ 16.15%
FY19Y/Y Change
Revenue
901.9M
↓ 8.93%
Net Income
-312.0M
↑ 103.92%
Net Profit Margin
-34.59%
↓ 19.14%
FY20Y/Y Change
Revenue
1.4B
↑ 59.15%
Net Income
30.6M
↓ 109.8%
Net Profit Margin
2.13%
↑ 36.72%
FY21Y/Y Change
Revenue
1.8B
↑ 23.64%
Net Income
-29.5M
↓ 196.45%
Net Profit Margin
-1.66%
↓ 3.79%
FY22Y/Y Change
Revenue
1.0B
↓ 43.42%
Net Income
-328.0M
↑ 1011.86%
Net Profit Margin
-32.66%
↓ 31.0%
FY23Y/Y Change
Revenue
863.5M
↓ 14.01%
Net Income
-188.9M
↓ 42.42%
Net Profit Margin
-21.87%
↑ 10.79%
Q3 FY22Q/Q Change
Revenue
179.7M
↓ 42.0%
Net Income
-86.0M
↓ 15.12%
Net Profit Margin
-47.87%
↓ 15.15%
Q4 FY22Q/Q Change
Revenue
185.4M
↑ 3.15%
Net Income
-85.2M
↓ 0.99%
Net Profit Margin
-45.95%
↑ 1.92%
Q1 FY23Q/Q Change
Revenue
237.6M
↑ 28.16%
Net Income
-18.2M
↓ 78.64%
Net Profit Margin
-7.66%
↑ 38.29%
Q2 FY23Q/Q Change
Revenue
265.4M
↑ 11.71%
Net Income
-19.6M
↑ 7.91%
Net Profit Margin
-7.4%
↑ 0.26%
Q3 FY23Q/Q Change
Revenue
178.6M
↓ 32.71%
Net Income
-84.5M
↑ 330.24%
Net Profit Margin
-47.31%
↓ 39.91%
Q4 FY23Q/Q Change
Revenue
181.9M
↑ 1.85%
Net Income
-66.5M
↓ 21.29%
Net Profit Margin
-36.56%
↑ 10.75%
FY18Y/Y Change
Total Assets
2.5B
↓ 5.36%
Total Liabilities
659.8M
↓ 11.59%
FY19Y/Y Change
Total Assets
2.3B
↓ 5.79%
Total Liabilities
694.5M
↑ 5.26%
FY20Y/Y Change
Total Assets
2.5B
↑ 7.09%
Total Liabilities
801.5M
↑ 15.41%
FY21Y/Y Change
Total Assets
2.4B
↓ 2.97%
Total Liabilities
714.6M
↓ 10.84%
FY22Y/Y Change
Total Assets
2.2B
↓ 9.68%
Total Liabilities
605.7M
↓ 15.24%
FY23Y/Y Change
Total Assets
2.0B
↓ 7.18%
Total Liabilities
622.5M
↑ 2.77%
Q3 FY22Q/Q Change
Total Assets
2.2B
↓ 6.11%
Total Liabilities
595.7M
↓ 8.46%
Q4 FY22Q/Q Change
Total Assets
2.2B
↓ 2.58%
Total Liabilities
605.7M
↑ 1.68%
Q1 FY23Q/Q Change
Total Assets
2.2B
↑ 0.11%
Total Liabilities
617.8M
↑ 2.0%
Q2 FY23Q/Q Change
Total Assets
2.2B
↓ 0.49%
Total Liabilities
623.6M
↑ 0.93%
Q3 FY23Q/Q Change
Total Assets
2.1B
↓ 4.73%
Total Liabilities
612.1M
↓ 1.84%
Q4 FY23Q/Q Change
Total Assets
2.0B
↓ 2.19%
Total Liabilities
622.5M
↑ 1.7%
FY18Y/Y Change
Operating Cash Flow
-109.1M
↑ 18.53%
Investing Cash Flow
-26.1M
↓ 44.03%
Financing Cash Flow
140.9M
↑ 130.84%
FY19Y/Y Change
Operating Cash Flow
-172.5M
↑ 58.07%
Investing Cash Flow
-13.3M
↓ 49.19%
Financing Cash Flow
175.2M
↑ 24.37%
FY20Y/Y Change
Operating Cash Flow
39.5M
↓ 122.88%
Investing Cash Flow
-18.3M
↑ 38.11%
Financing Cash Flow
-35.1M
↓ 120.02%
FY21Y/Y Change
Operating Cash Flow
38.3M
↓ 2.89%
Investing Cash Flow
35.9M
↓ 296.15%
Financing Cash Flow
-10.4M
↓ 70.49%
Q3 FY22Q/Q Change
Operating Cash Flow
-32.2M
↑ 180.87%
Investing Cash Flow
-4.7M
↓ 104.32%
Financing Cash Flow
8.4M
↓ 31.2%
Q4 FY22Q/Q Change
Operating Cash Flow
-31.6M
↓ 1.91%
Investing Cash Flow
-5.5M
↑ 17.28%
Financing Cash Flow
10.1M
↑ 20.13%
Q1 FY23Q/Q Change
Operating Cash Flow
-22.6M
↓ 28.38%
Investing Cash Flow
-7.7M
↑ 40.54%
Financing Cash Flow
-13.1M
↓ 229.33%
Q2 FY23Q/Q Change
Operating Cash Flow
-365.0K
↓ 98.39%
Investing Cash Flow
-5.5M
↓ 28.85%
Financing Cash Flow
3.5M
↓ 126.39%

Technicals Summary

Sell

Neutral

Buy

Opko Health, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Opko Health, Inc.
Opko Health, Inc.
38.2%
-4.65%
-11.51%
-70.22%
-47.44%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-10.04%
11.56%
-2.91%
-10.51%
114.97%
Agilent Technologies Inc.
Agilent Technologies Inc.
-9.88%
21.51%
-2.07%
0.2%
75.64%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-6.08%
17.32%
-3.74%
12.94%
110.27%
Danaher Corp.
Danaher Corp.
-6.42%
14.42%
-5.17%
-2.62%
85.63%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-9.75%
23.72%
14.85%
5.05%
69.75%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Opko Health, Inc.
Opko Health, Inc.
NA
NA
-2.87
-0.37
-0.13
-0.05
NA
1.8
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
47.4
47.4
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
31.68
31.68
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.1
35.1
2.81
21.55
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
41.83
41.83
3.13
7.62
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
31.29
31.29
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Opko Health, Inc.
Opko Health, Inc.
Buy
$857.3M
-47.44%
NA
-21.87%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$39.7B
114.97%
47.4
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.8B
75.64%
31.68
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$206.7B
110.27%
35.1
13.99%
Danaher Corp.
Danaher Corp.
Buy
$175.0B
85.63%
41.83
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$41.5B
69.75%
31.29
9.06%

Institutional Holdings

  • Vanguard Group Inc

    5.70%
  • BlackRock Inc

    5.30%
  • Geode Capital Management, LLC

    1.39%
  • State Street Corporation

    1.34%
  • D. E. Shaw & Co LP

    0.88%
  • Goldman Sachs Group Inc

    0.83%

Corporate Announcements

  • Opko Health, Inc. Earnings

    Opko Health, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-­4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-­1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig

Organization
Opko Health, Inc.
Employees
3930
CEO
Dr. Phillip Frost Ph.D.
Industry
Health Technology

FAQs